Long Term Efficacy and Assessment of Tumor Response of Transarterial Chemoembolization in Neuroendocrine Liver Metastases: A 15-Year Monocentric Experience

Background: transarterial chemoembolization (TACE) is an established treatment for neuroendocrine tumor (NET) liver metastases. The aim was to evaluate the long-term treatment efficacy of TACE for NET liver metastases, and correlate imaging response with survival. Methods: this IRB-approved, single-...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Caroline Touloupas, Matthieu Faron, Julien Hadoux, Frédéric Deschamps, Charles Roux, Maxime Ronot, Steven Yevich, Julien Joskin, Maximiliano Gelli, Rémy Barbé, Livia Lamartina, Hubert Tissot, Jean-Yves Scoazec, David Malka, Michel Ducreux, Eric Baudin, Thierry de Baère, Lambros Tselikas
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	neuroendocrine neoplasms chemoembolization intra-arterial therapies RECIST mRECIST liver metastases Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/614aa245f54a47eaaef8d3d1a6f5ff24
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:614aa245f54a47eaaef8d3d1a6f5ff24
record_format	dspace
spelling	oai:doaj.org-article:614aa245f54a47eaaef8d3d1a6f5ff242021-11-11T15:29:17ZLong Term Efficacy and Assessment of Tumor Response of Transarterial Chemoembolization in Neuroendocrine Liver Metastases: A 15-Year Monocentric Experience10.3390/cancers132153662072-6694https://doaj.org/article/614aa245f54a47eaaef8d3d1a6f5ff242021-10-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/21/5366https://doaj.org/toc/2072-6694Background: transarterial chemoembolization (TACE) is an established treatment for neuroendocrine tumor (NET) liver metastases. The aim was to evaluate the long-term treatment efficacy of TACE for NET liver metastases, and correlate imaging response with survival. Methods: this IRB-approved, single-center, retrospective study evaluated all TACE procedures performed for NET liver metastases from 2003–2017 for imaging tumor response (RECIST and mRECIST), time to liver progression (TT<sub>L</sub>P), time to untreatable progression with TACE (TTUP), and overall survival (OS). Patient, tumor, and treatment characteristics were analyzed as prognostic factors. Survival curves according to the Kaplan–Meier method were compared by Log-rank test. Tumor responses according to RECIST and mRECIST were correlated with OS. Results: 555 TACE procedures were performed in 202 NET patients (38% grade 1, 60% grade 2) with primary tumors originating from pancreas, small bowel, and lung (39, 26, and 22% respectively). Median follow-up was 8.2 years (90–139 months). Median TT<sub>L</sub>P and TTUP were 19.3 months (95%CI 16.3–22.3) and 26.2 months (95%CI 22.3–33.1), respectively. Median OS was 5.3 years (95%CI 4.2–6.7), and was higher among mRECIST responders (80.5 months; 95%CI 64.6–89.8) than in non-responders (39.6 months; 95%CI = 32.8–60.2; <i>p</i> < 0.001). In multivariable analysis, age, tumor grade and liver involvement predicted worse OS, whereas administration of somatostatin analogs correlated with improved OS. Conclusion: TACE for NET liver metastases provides objective response and sustained local disease control rates. RECIST and mRECIST responses correlate with OS.Caroline TouloupasMatthieu FaronJulien HadouxFrédéric DeschampsCharles RouxMaxime RonotSteven YevichJulien JoskinMaximiliano GelliRémy BarbéLivia LamartinaHubert TissotJean-Yves ScoazecDavid MalkaMichel DucreuxEric BaudinThierry de BaèreLambros TselikasMDPI AGarticleneuroendocrine neoplasmschemoembolizationintra-arterial therapiesRECISTmRECISTliver metastasesNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5366, p 5366 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	neuroendocrine neoplasms chemoembolization intra-arterial therapies RECIST mRECIST liver metastases Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	neuroendocrine neoplasms chemoembolization intra-arterial therapies RECIST mRECIST liver metastases Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Caroline Touloupas Matthieu Faron Julien Hadoux Frédéric Deschamps Charles Roux Maxime Ronot Steven Yevich Julien Joskin Maximiliano Gelli Rémy Barbé Livia Lamartina Hubert Tissot Jean-Yves Scoazec David Malka Michel Ducreux Eric Baudin Thierry de Baère Lambros Tselikas Long Term Efficacy and Assessment of Tumor Response of Transarterial Chemoembolization in Neuroendocrine Liver Metastases: A 15-Year Monocentric Experience
description	Background: transarterial chemoembolization (TACE) is an established treatment for neuroendocrine tumor (NET) liver metastases. The aim was to evaluate the long-term treatment efficacy of TACE for NET liver metastases, and correlate imaging response with survival. Methods: this IRB-approved, single-center, retrospective study evaluated all TACE procedures performed for NET liver metastases from 2003–2017 for imaging tumor response (RECIST and mRECIST), time to liver progression (TT<sub>L</sub>P), time to untreatable progression with TACE (TTUP), and overall survival (OS). Patient, tumor, and treatment characteristics were analyzed as prognostic factors. Survival curves according to the Kaplan–Meier method were compared by Log-rank test. Tumor responses according to RECIST and mRECIST were correlated with OS. Results: 555 TACE procedures were performed in 202 NET patients (38% grade 1, 60% grade 2) with primary tumors originating from pancreas, small bowel, and lung (39, 26, and 22% respectively). Median follow-up was 8.2 years (90–139 months). Median TT<sub>L</sub>P and TTUP were 19.3 months (95%CI 16.3–22.3) and 26.2 months (95%CI 22.3–33.1), respectively. Median OS was 5.3 years (95%CI 4.2–6.7), and was higher among mRECIST responders (80.5 months; 95%CI 64.6–89.8) than in non-responders (39.6 months; 95%CI = 32.8–60.2; <i>p</i> < 0.001). In multivariable analysis, age, tumor grade and liver involvement predicted worse OS, whereas administration of somatostatin analogs correlated with improved OS. Conclusion: TACE for NET liver metastases provides objective response and sustained local disease control rates. RECIST and mRECIST responses correlate with OS.
format	article
author	Caroline Touloupas Matthieu Faron Julien Hadoux Frédéric Deschamps Charles Roux Maxime Ronot Steven Yevich Julien Joskin Maximiliano Gelli Rémy Barbé Livia Lamartina Hubert Tissot Jean-Yves Scoazec David Malka Michel Ducreux Eric Baudin Thierry de Baère Lambros Tselikas
author_facet	Caroline Touloupas Matthieu Faron Julien Hadoux Frédéric Deschamps Charles Roux Maxime Ronot Steven Yevich Julien Joskin Maximiliano Gelli Rémy Barbé Livia Lamartina Hubert Tissot Jean-Yves Scoazec David Malka Michel Ducreux Eric Baudin Thierry de Baère Lambros Tselikas
author_sort	Caroline Touloupas
title	Long Term Efficacy and Assessment of Tumor Response of Transarterial Chemoembolization in Neuroendocrine Liver Metastases: A 15-Year Monocentric Experience
title_short	Long Term Efficacy and Assessment of Tumor Response of Transarterial Chemoembolization in Neuroendocrine Liver Metastases: A 15-Year Monocentric Experience
title_full	Long Term Efficacy and Assessment of Tumor Response of Transarterial Chemoembolization in Neuroendocrine Liver Metastases: A 15-Year Monocentric Experience
title_fullStr	Long Term Efficacy and Assessment of Tumor Response of Transarterial Chemoembolization in Neuroendocrine Liver Metastases: A 15-Year Monocentric Experience
title_full_unstemmed	Long Term Efficacy and Assessment of Tumor Response of Transarterial Chemoembolization in Neuroendocrine Liver Metastases: A 15-Year Monocentric Experience
title_sort	long term efficacy and assessment of tumor response of transarterial chemoembolization in neuroendocrine liver metastases: a 15-year monocentric experience
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/614aa245f54a47eaaef8d3d1a6f5ff24
work_keys_str_mv	AT carolinetouloupas longtermefficacyandassessmentoftumorresponseoftransarterialchemoembolizationinneuroendocrinelivermetastasesa15yearmonocentricexperience AT matthieufaron longtermefficacyandassessmentoftumorresponseoftransarterialchemoembolizationinneuroendocrinelivermetastasesa15yearmonocentricexperience AT julienhadoux longtermefficacyandassessmentoftumorresponseoftransarterialchemoembolizationinneuroendocrinelivermetastasesa15yearmonocentricexperience AT fredericdeschamps longtermefficacyandassessmentoftumorresponseoftransarterialchemoembolizationinneuroendocrinelivermetastasesa15yearmonocentricexperience AT charlesroux longtermefficacyandassessmentoftumorresponseoftransarterialchemoembolizationinneuroendocrinelivermetastasesa15yearmonocentricexperience AT maximeronot longtermefficacyandassessmentoftumorresponseoftransarterialchemoembolizationinneuroendocrinelivermetastasesa15yearmonocentricexperience AT stevenyevich longtermefficacyandassessmentoftumorresponseoftransarterialchemoembolizationinneuroendocrinelivermetastasesa15yearmonocentricexperience AT julienjoskin longtermefficacyandassessmentoftumorresponseoftransarterialchemoembolizationinneuroendocrinelivermetastasesa15yearmonocentricexperience AT maximilianogelli longtermefficacyandassessmentoftumorresponseoftransarterialchemoembolizationinneuroendocrinelivermetastasesa15yearmonocentricexperience AT remybarbe longtermefficacyandassessmentoftumorresponseoftransarterialchemoembolizationinneuroendocrinelivermetastasesa15yearmonocentricexperience AT livialamartina longtermefficacyandassessmentoftumorresponseoftransarterialchemoembolizationinneuroendocrinelivermetastasesa15yearmonocentricexperience AT huberttissot longtermefficacyandassessmentoftumorresponseoftransarterialchemoembolizationinneuroendocrinelivermetastasesa15yearmonocentricexperience AT jeanyvesscoazec longtermefficacyandassessmentoftumorresponseoftransarterialchemoembolizationinneuroendocrinelivermetastasesa15yearmonocentricexperience AT davidmalka longtermefficacyandassessmentoftumorresponseoftransarterialchemoembolizationinneuroendocrinelivermetastasesa15yearmonocentricexperience AT michelducreux longtermefficacyandassessmentoftumorresponseoftransarterialchemoembolizationinneuroendocrinelivermetastasesa15yearmonocentricexperience AT ericbaudin longtermefficacyandassessmentoftumorresponseoftransarterialchemoembolizationinneuroendocrinelivermetastasesa15yearmonocentricexperience AT thierrydebaere longtermefficacyandassessmentoftumorresponseoftransarterialchemoembolizationinneuroendocrinelivermetastasesa15yearmonocentricexperience AT lambrostselikas longtermefficacyandassessmentoftumorresponseoftransarterialchemoembolizationinneuroendocrinelivermetastasesa15yearmonocentricexperience
_version_	1718435240456749056

Long Term Efficacy and Assessment of Tumor Response of Transarterial Chemoembolization in Neuroendocrine Liver Metastases: A 15-Year Monocentric Experience

Ejemplares similares